Erectile dysfunction in testicular cancer patients treated with chemotherapy

Basit Öğe Kaydı
dc.authoridharputluoglu, hakan/0000-0001-8537-5941
dc.authoridFirdolas, Fatih/0000-0003-2097-9853;
dc.authorwosidharputluoglu, hakan/ABI-6451-2020
dc.authorwosidFirdolas, Fatih/W-7682-2018
dc.authorwosidaltintas, ramazan/AAP-2348-2020
dc.contributor.authorTasdemir, C.
dc.contributor.authorFirdolas, F.
dc.contributor.authorHarputluoglu, H.
dc.contributor.authorAltintas, R.
dc.contributor.authorGunes, A.
dc.date.accessioned2024-08-04T20:36:00Z
dc.date.available2024-08-04T20:36:00Z
dc.date.issued2012
dc.departmentİnönü Üniversitesien_US
dc.description.abstractInformation on male potency in testicular cancer (TC) patients treated with chemotherapy is insufficient. We aimed to assess the levels of depression and anxiety symptoms, sexual function and gonodotrophins. Participants (n similar to=similar to 27) were identified and recruited from the genitourinary services of two medical centres, one in Inonu University and the other in the Firat University. All patients are TC patients treated with chemotherapy after unilateral orchiectomy. Participants completed follow-up assessments after the completion of the chemotherapy regimen. Serum luteinising hormone, follicle-stimulating hormone and testosterone levels were determined after blood samples had been taken in the morning after an overnight fast. International Index of Erectile Function (IIEF-15) was also used to evaluate erectile dysfunction (ED) score. Beck Depression and Beck Anxiety Scale were used to assess psychological symptoms. The findings indicated that men treated with chemotherapy had significantly different IIEF-15 and Beck Anxiety scores compared with men who did not receive chemotherapy. But no statistically significant difference was determined in the serum gonodotrophin levels and depression score between the two groups. It is concluded that patients with TC undergoing chemotherapy have greater risk than normal men for ED, independently of the gonodotrophin's level.en_US
dc.identifier.doi10.1111/j.1439-0272.2011.01271.x
dc.identifier.endpage229en_US
dc.identifier.issn0303-4569
dc.identifier.issn1439-0272
dc.identifier.issue4en_US
dc.identifier.pmid22248116en_US
dc.identifier.scopus2-s2.0-84863218806en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage226en_US
dc.identifier.urihttps://doi.org/10.1111/j.1439-0272.2011.01271.x
dc.identifier.urihttps://hdl.handle.net/11616/95707
dc.identifier.volume44en_US
dc.identifier.wosWOS:000305822400002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofAndrologiaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChemotherapyen_US
dc.subjecterectile dysfunctionen_US
dc.subjecttesticular canceren_US
dc.titleErectile dysfunction in testicular cancer patients treated with chemotherapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu